Leucid Bio to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
London, UK – 28 August 2025 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary lateral CAR platform, today announced that it will attend the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. Filippo Petti, Chief Executive Officer, will participate in a fireside chat at 1:05 p.m. ET on Monday, September 8, 2025. Company management will also participate in one-on-one meetings at the conference.
